Acasti Pharma Inc. Reports Positive Test Results (NEPT)

Acasti Pharma Inc., a subsidiary of Neptune Technologies & Bioressources Inc. NEPT reports significant results on the effects of its anti-dyslipidemic investigational drug candidate CaPre™ on C-reactive protein levels, a biomarker of CardioVascular Disease risk and associated with diabetes and obesity. Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsConsumer StaplesPersonal Products
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!